首页> 外文期刊>Orthopaedic Journal of Sports Medicine >Evaluation of the Consistency and Composition of Commercially Available Bone Marrow Aspirate Concentrate Systems
【24h】

Evaluation of the Consistency and Composition of Commercially Available Bone Marrow Aspirate Concentrate Systems

机译:商业上可获得的骨髓抽吸浓缩系统的稠度和组成的评价

获取原文
           

摘要

Background: Bone marrow aspirate (BMA) concentrate (BMAC) has gained popularity as a treatment modality for various orthopaedic conditions; however, there are still inconsistencies in its reported therapeutic efficacy. This may be because of the many different commercial BMAC preparation systems used clinically, which generate dissimilar concentrate products. Purpose: To compare 3 commercially available BMAC preparation systems: Harvest SmartPrep 3, Biomet BioCUE, and Arthrex Angel. We evaluated the consistency of each of these systems and compared the composition of their concentrate products. Study Design: Controlled laboratory study. Methods: A total of 10 patients donated whole blood and BMA, which were combined and processed with the 3 different BMAC preparation systems. Samples were taken before and after processing for the measurement of white blood cells (WBC), platelets (PLT), CD34+ cells, and colony-forming unit–fibroblast (CFU-F). To evaluate consistency, the variances of cell yield and concentration increase from baseline for each cell type were compared between systems. To compare concentrate product composition, differences between the systems’ mean cell yield and concentration increase from baseline for each cell type were evaluated. Results: The Harvest system (variance, 0.25) concentrated WBC more consistently than the Arthrex system (variance, 3.25) ( P = .024), but no other differences in consistency were noted between the 3 systems. The Harvest system recovered the greatest percentage of CFU-F (82.4% ± 18.2%), CD34+ cells (81.1% ± 28.5%), and WBC (77.3% ± 8.6%), whereas the Biomet system recovered the greatest percentage of PLTs (92.9% ± 27.3%). The Arthrex system concentrated PLT to the greatest degree (11.10 ± 2.05 times baseline), while the Biomet system concentrated WBC to the greatest degree (5.99 ± 1.04 times baseline). Conclusion: The consistency of the 3 systems was similar for all but 1 of the evaluated cell types. However, the composition of the concentrate products differed across systems. This may grant each system unique advantages without having to sacrifice reproducibility. Clinical Relevance: Understanding the consistency of different BMAC preparation systems and their product makeup may aid in determining optimal therapeutic doses of different cell types.
机译:背景:骨髓抽吸物(BMA)浓缩物(BMAC)对各种整形外科病症的治疗方式获得了普及;然而,其报告的治疗疗效仍存在不一致。这可能是因为许多不同的商业BMAC制剂系统临床上使用,其产生不同的浓缩产品。目的:比较3个商用BMAC制备系统:收获SmartPrep 3,Biomet Biocue和Arthrex Angel。我们评估了这些系统中的每一个的一致性,并比较了它们的浓缩产品的组成。研究设计:受控实验室研究。方法:总共10名患者捐赠全血和BMA,用3种不同的BMAC制备系统合并并加工。在处理白细胞(WBC),血小板(PLT),CD34 +细胞和集落的单位成纤维细胞(CFU-F)的下和后,进行样品。为了评估一致性,在系统之间比较了细胞产率和从每个细胞类型的基线增加的差异。为了比较集中产品组成,评估系统平均细胞产量与每种细胞类型基线的平均细胞产率和浓度之间的差异。结果:收获系统(方差0.25)比Arthrex系统更始终浓缩WBC(方差,3.25)(P = .024),但在3个系统之间没有省略其余的差异。收获系统恢复了CFU-F(82.4%±18.2%),CD34 +细胞(81.1%±28.5%)和WBC(77.3%±8.6%)的最大百分比,而BIomet系统恢复了最大百分比的PLTS( 92.9%±27.3%)。 ARTHREX系统集中了PLT,最大程度(11.10±2.05倍的基线),而BIOMET系统集中在最大程度上的WBC(5.99±1.04倍基线)。结论:3个系统的一致性对评估的细胞类型的所有除1中相似。然而,浓缩产物的组成在系统上不同。这可能会授予每个系统的独特优势,而无需牺牲再现性。临床相关性:了解不同BMAC制备系统的一致性及其产品化妆品可有助于确定不同细胞类型的最佳治疗剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号